Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630846 · ClinicalTrials.gov registry record · Phase 2
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 801
- Enrollment target
NCT05630846: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT05630846 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 801 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (502% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05630846, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 801 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
Primary Outcome
Anti-measles antibodies were measured with multiplex luminex based immuno assay and the results were expressed as GMC, in milli international units per milliliter (mIU/mL). Analysis was performed on per protocol set which included all eligible participants who received study intervention as per protocol, were not unblinded, had immunogenicity results pre- and post-dose for at least 1 antigen, complied with blood draw interval between study intervention and post- dose blood sample, without interc
Interventions
- BIOLOGICAL Investigational MMRV(H)NS vaccine
- BIOLOGICAL Investigational MM(H)RVNS vaccine
- BIOLOGICAL Investigational M(L)M(L)R(L)V(L)NS vaccine
- BIOLOGICAL Marketed MMRV_Lot 1 and Lot 2 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 2 |
What the finished NCT05630846 record still lists
NCT05630846 is an interventional study that assigns participants to a tested intervention. The registered 801 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (502% higher).
The record links to 0 conditions, and to 4 interventions - of which Investigational MMRV(H)NS vaccine is the first listed.
NCT05630846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05630846 about?
NCT05630846 is a clinical study titled "A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age". The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
What is the current status of trial NCT05630846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 801 participants. The study started on 2022-12-14. Estimated completion is 2024-10-14.
What interventions are being tested in trial NCT05630846?
The interventions under investigation include: Investigational MMRV(H)NS vaccine (BIOLOGICAL), Investigational MM(H)RVNS vaccine (BIOLOGICAL), Investigational M(L)M(L)R(L)V(L)NS vaccine (BIOLOGICAL), Marketed MMRV_Lot 1 and Lot 2 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05630846?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05630846's enrollment target sits among peer trials
801 37th of 2000 higher than 1,964 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI